Drugs / AMXI-5001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04503265 | Aug 2020 → Aug 2026 overdue | breast cancer, malignant pancreatic neoplasm, ovarian cancer, prostate cancer | AtlasMedx, Incorporated | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMXI-5001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04503265 ↗ |
| Action | Inhibit | “AMXI-5001 is an orally available dual PARP (poly adenosine diphosphate \[ADP\] ribose polymerase) and microtubule polymerization inhibitor.” NCT04503265 ↗ |
| Route | Oral | “AMXI-5001 is administered orally twice daily” NCT04503265 ↗ |